Cargando…

Emerging treatments in management of prostate cancer: biomarker validation and endpoints for immunotherapy clinical trial design

The rapidly emerging field of immunotherapy and the development of novel immunologic agents that have been approved in melanoma and successfully studied in lung cancer, kidney cancer, and prostate cancer have mandated that there be uniformity in clinical trial analysis beyond conventional survival e...

Descripción completa

Detalles Bibliográficos
Autor principal: Slovin, Susan F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918229/
https://www.ncbi.nlm.nih.gov/pubmed/27471695
http://dx.doi.org/10.2147/ITT.S30821
_version_ 1782439083414388736
author Slovin, Susan F
author_facet Slovin, Susan F
author_sort Slovin, Susan F
collection PubMed
description The rapidly emerging field of immunotherapy and the development of novel immunologic agents that have been approved in melanoma and successfully studied in lung cancer, kidney cancer, and prostate cancer have mandated that there be uniformity in clinical trial analysis beyond conventional survival endpoints and imaging. This includes some measure of determining whether the immunologic target is hit and how the treatment has impacted on the immune system in toto. While melanoma is leading the field towards these ends, there is some doubt that not all of the recent successes with immune therapies, for example, checkpoint inhibitors, will be effective for every cancer, and that the toxicities may also be different depending on the malignancy. This review serves to elucidate the current issues facing clinical investigators who perform immunologic trials targeted at patients with prostate cancer and discusses the challenges in assessing the right immunologic endpoints to demonstrate biologic/immunologic targeting leading to clinical benefit.
format Online
Article
Text
id pubmed-4918229
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-49182292016-07-28 Emerging treatments in management of prostate cancer: biomarker validation and endpoints for immunotherapy clinical trial design Slovin, Susan F Immunotargets Ther Review The rapidly emerging field of immunotherapy and the development of novel immunologic agents that have been approved in melanoma and successfully studied in lung cancer, kidney cancer, and prostate cancer have mandated that there be uniformity in clinical trial analysis beyond conventional survival endpoints and imaging. This includes some measure of determining whether the immunologic target is hit and how the treatment has impacted on the immune system in toto. While melanoma is leading the field towards these ends, there is some doubt that not all of the recent successes with immune therapies, for example, checkpoint inhibitors, will be effective for every cancer, and that the toxicities may also be different depending on the malignancy. This review serves to elucidate the current issues facing clinical investigators who perform immunologic trials targeted at patients with prostate cancer and discusses the challenges in assessing the right immunologic endpoints to demonstrate biologic/immunologic targeting leading to clinical benefit. Dove Medical Press 2013-12-16 /pmc/articles/PMC4918229/ /pubmed/27471695 http://dx.doi.org/10.2147/ITT.S30821 Text en © 2014 Slovin. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Slovin, Susan F
Emerging treatments in management of prostate cancer: biomarker validation and endpoints for immunotherapy clinical trial design
title Emerging treatments in management of prostate cancer: biomarker validation and endpoints for immunotherapy clinical trial design
title_full Emerging treatments in management of prostate cancer: biomarker validation and endpoints for immunotherapy clinical trial design
title_fullStr Emerging treatments in management of prostate cancer: biomarker validation and endpoints for immunotherapy clinical trial design
title_full_unstemmed Emerging treatments in management of prostate cancer: biomarker validation and endpoints for immunotherapy clinical trial design
title_short Emerging treatments in management of prostate cancer: biomarker validation and endpoints for immunotherapy clinical trial design
title_sort emerging treatments in management of prostate cancer: biomarker validation and endpoints for immunotherapy clinical trial design
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918229/
https://www.ncbi.nlm.nih.gov/pubmed/27471695
http://dx.doi.org/10.2147/ITT.S30821
work_keys_str_mv AT slovinsusanf emergingtreatmentsinmanagementofprostatecancerbiomarkervalidationandendpointsforimmunotherapyclinicaltrialdesign